The central question of type 2 diabetes.
Type 2 diabetes (T2D) represents a significant global epidemic with more than 285 million people affected worldwide. Regulating glycemia in T2D patients can be partially achieved with currently available treatment, but intensive research during the last decades have led to the discovery of modified compounds or new targets that could represent great hope for safe and effective treatment in the future. Among them, targets in the CNS that are known to control feeding and body weight have been also shown to exert glucoregulatory actions, and could be a key in the development of a new generation of drugs in the field of T2D. Such drugs would be of great interest since they can be used both in the treatment of diabetes and obesity. This patent review aims to establish an overview of recent patents disclosing new therapeutic opportunities targeting peripheral, as well as central targets for the treatment of T2D.
Biomeostasis, Nutritional Behavior & Metabolic Disorders, Faculty of Sciences & Technology Service B52, Escadrille Normandie-Niemen Avenue, Aix-Marseilles University, 13397 Marseilles, France.
Thaïs
T
Rouquet
Marion S
MS
Bonnet
Clément
C
Pierre
Michel
M
Dallaporta
Jean-Denis
JD
Troadec
Julien
J
Roux
Bruno
B
Bariohay
D000818:Animals; D002490:Central Nervous System / Q000502:physiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005947:Glucose / Q000378:metabolism; D006801:Humans
D005947:Glucose